Description: Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.
Home Page: www.sareum.com
Langford Arch
Cambridge,
CB22 3FX
United Kingdom
Phone:
44 1223 497 700
Officers
| Name | Title |
|---|---|
| Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D. | Executive Chairman |
| Dr. John Charles Reader Ph.D. | Founder, Chief Scientific Officer & Executive Director |
| Dr. Timothy John Mitchell Ph.D. | Founder, COO & Executive Director |
| Mr. Clive H. W. Birch F.C.A. | Secretary & Senior Independent Non-Executive Director |
| Alexandra Harrison | Head of IR |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.3729 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 5 |